A Phase 4 interventional study of Recombinant FSH (follitropin alpha) in Ovulation Induction, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 3 sites in 3 countries. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2014-02-13.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.
Among the 30 studies testing follitropin alfa in Infertility, this one is the 4th largest by enrollment, is one of 3 that started in 2009, is one of 13 in phase 4, and was the 8th registered.
2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:
Vietnam Military Medical University · Sites in Vietnam
Ages 18–34 · Women only
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Sites in Japan
Ages 18–42 · Women only
Nanjing University · Sites in China
Ages 35–40 · Women only
By country, each count listing its studies:
follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 37 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 310 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 159 across the 30 interventional studies. Of the 23 that completed or were terminated, 10 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 30 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
44 studies in Infertility by Merck KGaA, Darmstadt, Germany: 1 open now, 1 under way, 1 of them phase 3. Of 43 finished, 21 (49%) have results posted.
Among the 44 studies in Infertility by Merck KGaA, Darmstadt, Germany, this one is the 4th largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2009, is one of 9 in phase 4, and was the 15th registered.
Merck KGaA, Darmstadt, Germany’s Infertility studies by the year they started, since 1999.
2 of the studies testing follitropin alfa in Infertility that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340827Phase 3Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyA Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) | 2027-09-30 |
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 30 studies testing follitropin alfa in Infertility, from their registry updates:
Among Merck KGaA, Darmstadt, Germany’s 44 in Infertility:
This tab as a report to print or save as PDF → With an account.
This is an open-label, prospective, randomized, controlled, multicentric, multinational, phase IV study to evaluate the use of Gonal-f in inducing ovulation in female subjects with chronic anovulation. It has been observed that conventional high dose set up regimen of gonadotropin and human chorionic gonadotropin (hCG) is effective in anovulatory subjects in terms of overall pregnancy rates. However, development of multiple follicles leading to multiple pregnancy and/or ovarian hyperstimulation syndrome (OHSS) is the major complications associated with this high dose set up. Chronic low-dose (CLD) protocols of follicle stimulating hormone (FSH), aimed at finding the threshold amount of FSH necessary to promote monofolliculogenesis, have been found to be successful in reducing the rate of OHSS almost to nil and the rate of multiple pregnancies to a minimum. This post-marketing study will investigate tailoring of recombinant follicle stimulating hormone (r-FSH) in a large population (N=310) of subjects from a region (North Africa/Middle East) that has not been included in previous studies of ovulation induction in subjects with chronic anovulation. The study aims to increase current knowledge of the efficacy and safety of Gonal-f, and provide fertility physicians with experience in Gonal-f treatment in anovulatory infertility, thereby contributing to the development of FSH dosing guidelines for ovulation induction by defining the optimal CLD and Low dose (LD) regimens.
Gonal-f is a recombinant form of human FSH (r-hFSH), an endogenous gonadotropin which is being produced in genetically engineered chinese hamster ovary cells and is indicated for induction of ovulation and pregnancy in anovulatory infertile women in whom the cause of infertility is functional and not due to primary ovarian failure. It is also indicated for the development of multiple follicles in ovulatory women participating in an assisted reproductive technology (ART) programme, such as in in vitro fertilization (IVF). The primary cause of infertility in women is an abnormality of ovulation. Most of these anovulatory subjects fall into the World Health Organization (WHO) Group II category, characterized by asynchronous gonadotropin and oestrogen production and normal levels of prolactin (PRL). These subjects present with a variety of menstrual disorders, most commonly polycystic ovarian syndrome (PCOS).
Gonal-f is administered as a course of daily injections, subcutaneously into the anterior abdominal wall. A commonly used regimen commences at 75-150 IU FSH daily and is increased preferably by 37.5 IU, or 75 IU at 7 or preferably 14 day intervals if necessary, to obtain an adequate but not excessive response. A single injection of 5,000 IU urinary hCG (u-hCG) (or 250 microgram [mcg] r-hCG) should be administered after the last dose of Gonal-f and when the leading follicle has reached 17 mm in diameter. The subject is later recommended to have coitus on the day of, and the day following, hCG administration. The efficacy of Gonal-f in the treatment of WHO Group II anovulatory infertile women has been confirmed by 2 randomized, open-label, multicentric, phase III non-inferiority studies that compared Gonal-f with Metrodin® (urinary FSH) for ovulation induction. The possible serious adverse events (SAEs) associated with Gonal-f include OHSS and its possible complications, multiple pregnancies, pregnancy wastage, ectopic pregnancies and the possible risk of ovarian cancer and reproductive system neoplasms (e.g. endometrial, breast carcinoma).
OBJECTIVES
Primary objective:
Secondary objectives:
The study will enroll 310 eligible subjects, randomized in a 1:1 ratio to either Group I or II at the baseline visit prior to the first dose of FSH (pre-stimulation). Each subject will be refrained from the use of gonadotropins or any other ovulation stimulation therapy during the period from screening to the start of stimulation treatment. During the stimulation period, Gonal-f will be administered as a course of once daily (OD) injections, s.c. into the anterior abdominal wall through Gonal-f pen, according to either one of the following 2 step-up, low-dose regimens:
Group I: CLD regimen which recommends a starting dose of 75 IU and a first adjustment on Day 14 of stimulation, if no ovarian response is observed.
Group II: LD regimen which recommends a starting dose of 75 IU and a first adjustment on Day 7 of stimulation, if no ovarian response is observed.
For both groups, when at least 1 follicle reaches 10 to 12 mm in diameter, the Gonal-f administration will be maintained at that dose until the leading follicle reaches 17 mm or more in diameter and no more than 2 follicles have reached 14 mm in diameter. A single injection of hCG (5,000 IU u-hCG or 250 mcg r-hCG) will be administered intramuscularly or subcutaneously after the last Gonal-f injection, to trigger ovulation. Subjects will also be advised to have coitus on the day of, and the day following hCG administration. The total length of the stimulation treatment will not exceed 35 days unless an ultrasound assessment suggests imminent follicular growth and maturation and each subject will undergo one cycle of stimulation treatment only. Subjects will also be followed for a post stimulation period of up to 20 days after the triggering of ovulation by hCG injection, or cancellation of the cycle.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gonal-f will be injected on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 International Units (IU) for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 millimeter (mm) diameter, stimulation will be continued with the same dose for further 7 days. On Day 14 of stimulation, if no ovarian response is seen, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation would be made, depending on ovarian response.
Drug: Recombinant FSH (follitropin alpha)
Gonal-f will be administered on the second or third day of a spontaneous or progestogen-induced menstrual cycle (Day 0), with a daily dose of 75 IU for 7 days. Ovarian response will be assessed on Day 7 of stimulation by ultrasound scan. If no follicle has reached at least 10 to 12 mm diameter, the dose will be increased by 37.5 IU (total 112.5 IU) and administered for the next 7 days. Subsequent increments of 37.5 IU, at intervals of 7 days up to Day 35 of stimulation will be made, depending on ovarian response.
Drug: Recombinant FSH (follitropin alpha)
A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
Also known as: Gonal-f®, Follitropin alpha
Percentage of Participants With a Mono-follicular Development
Mono-follicular development was defined as the development of only 1 follicle of greater than or equal to (\>=) 17 millimeter (mm) diameter and no more than 2 other follicles larger than 14 mm in diameter at or before Days 35-42 of stimulation period assessed by means of a transvaginal ultrasound scan.
Time frame: Day 0 (first dose) up to Days 35-42 post human chorionic gonadotropin [hCG] administration (end of stimulation cycle {less than or equal to [<=] 35 days})
Number of Participants With Multi-follicular Development
Multi-follicular development was defined as the development of more than 3 follicles \>= 15 mm in diameter at or before Days 35-42 of stimulation period assessed by means of a transvaginal ultrasound scan.
Time frame: Day 0 (first dose) up to Days 35-42 post hCG administration (end of stimulation cycle {less than or equal to [<=] 35 days})
Number of Participants With Adverse Events (AEs)
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug.
Time frame: Day 0 (first dose) up to Days 35-42 post hCG administration (end of stimulation cycle {less than or equal to [<=] 35 days})
Number of Participants With Multiple Pregnancies
Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.
Time frame: Day 0 (first dose) up to Days 35-42 post hCG administration (end of stimulation cycle {less than or equal to [<=] 35 days})
Number of Participants With Injection Tolerability
Participants who did not show any injection site reactions such as pain, redness, bruises, swelling and irritation were considered to have injection tolerability.
Time frame: Day 0 (first dose) up to Days 35-42 post hCG administration (end of stimulation cycle {less than or equal to [<=] 35 days})
Number of Participants Who Received Human Chorionic Gonadotropin (hCG)
Time frame: End of stimulation cycle (less than or equal to [<=] 35 days)
Number of Participants With Cancelled Cycles
Participants with cancelled cycles were those who did not achieve adequate follicular formation (at least 17 mm) for hCG administration.
Time frame: End of stimulation cycle (less than or equal to [<=] 35 days)
Number of Participants With Clinical Pregnancies
Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
Time frame: Day 0 (first dose) up to Days 35-42 post hCG administration (end of stimulation cycle {less than or equal to [<=] 35 days})
Duration of Follicle Stimulating Hormone (FSH)
Time frame: End of stimulation cycle (less than or equal to [<=] 35 days)
Total Follicle Stimulating Hormone (FSH) Dose
Time frame: End of stimulation cycle (less than or equal to [<=] 35 days
Number of Participants Who Answered Ease of Use of Gonal-f® Pen Questionnaire
Ease of use of Gonal-f® pen was assessed through a questionnaire consisting of 23 questions and the number of participants who responded to the questionnaire was recorded.
Time frame: On hCG administration day (end of stimulation cycle {less than or equal to [<=] 35 days})
| Milestone | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Started | 155 | 155 |
| Assessed for efficacy | 122 | 125 |
| Completed | 95 | 94 |
| Not completed | 60 | 61 |
| Withdrew: Dosing error | 1 | 1 |
| Withdrew: Missing estradiol | 25 | 28 |
| Withdrew: Low antral follicle count | 1 | 0 |
| Withdrew: Overstimulation | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other | 33 | 30 |
Mono-follicular development was defined as the development of only 1 follicle of greater than or equal to (\>=) 17 millimeter (mm) diameter and no more than 2 other follicles larger than 14 mm in diameter at or before Days 35-42 of stimulation period assessed by means of a transvaginal ultrasound scan.
| percentage of participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Percentage of Participants With a Mono-follicular Development | 56.55 | 55.20 |
Multi-follicular development was defined as the development of more than 3 follicles \>= 15 mm in diameter at or before Days 35-42 of stimulation period assessed by means of a transvaginal ultrasound scan.
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants With Multi-follicular Development | 17 | 15 |
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug.
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 30 | 31 |
Multiple pregnancy is a pregnancy where more than one fetus develops simultaneously in the womb. There are two types of twinning-identical and fraternal. Identical twins represent the splitting of a single fertilized zygote (union of two gametes or male/female sex cells that produce a developing fetus) into two separate individuals.
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants With Multiple Pregnancies | 3 | 1 |
Participants who did not show any injection site reactions such as pain, redness, bruises, swelling and irritation were considered to have injection tolerability.
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants With Injection Tolerability | 54 | 54 |
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants Who Received Human Chorionic Gonadotropin (hCG) | 94 | 91 |
Participants with cancelled cycles were those who did not achieve adequate follicular formation (at least 17 mm) for hCG administration.
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants With Cancelled Cycles | 19 | 19 |
Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic pregnancy.
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants With Clinical Pregnancies | 19 | 18 |
| Days | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Duration of Follicle Stimulating Hormone (FSH) | 13.68 ± 6.33 | 12.85 ± 5.58 |
| IU | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Total Follicle Stimulating Hormone (FSH) Dose | 1119.41 ± 690.04 | 1155.47 ± 730.45 |
Ease of use of Gonal-f® pen was assessed through a questionnaire consisting of 23 questions and the number of participants who responded to the questionnaire was recorded.
| participants | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Number of Participants Who Answered Ease of Use of Gonal-f® Pen Questionnaire | 58 | 75 |
Collected over AEs were collected on an ongoing basis from day of written informed consent. All new AEs were recorded until the post-treatment safety, on day 35-42 post-hCG administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chronic Low Dose (CLD) Protocol | — | 0/155 (0%) | 30/155 (19.4%) |
| Low Dose (LD) Protocol | — | 1/155 (0.6%) | 30/155 (19.4%) |
| Event | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| Ectopic pregnancyReproductive system and breast disorders | 0/155 | 1/155 |
| Event | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol |
|---|---|---|
| HeadacheNervous system disorders | 10/155 | 14/155 |
| Abdominal painGastrointestinal disorders | 12/155 | 7/155 |
| DizzinessCardiac disorders | 1/155 | 5/155 |
| NauseaGastrointestinal disorders | 5/155 | 5/155 |
| Pain in stomachGastrointestinal disorders | 0/155 | 4/155 |
| Chest painGeneral disorders | 0/155 | 3/155 |
| Back painMusculoskeletal and connective tissue disorders | 3/155 | 3/155 |
| Abdominal colic painGastrointestinal disorders | 0/155 | 2/155 |
| Lower abdominal painGastrointestinal disorders | 2/155 | 1/155 |
| FeverGeneral disorders | 2/155 | 0/155 |
| Age, Continuous(years) | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol | Total |
|---|---|---|---|
| Mean | 27.51 ± 4.42 | 27.88 ± 4.33 | 27.70 ± 4.37 |
| Sex: Female, Male(Participants) | Chronic Low Dose (CLD) Protocol | Low Dose (LD) Protocol | Total |
|---|---|---|---|
| Female | 122 | 125 | 247 |
| Male | 0 | 0 | 0 |
The record gives a start of Mar 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Follitropin alfa
Merck KGaA, Darmstadt, Germany →